Three studies presented at the ASH Annual Meeting and Exposition highlight the emerging role CAR T-cell therapies have in treating certain types of aggressive, refractory blood cancers.

Conferences

Three studies presented at the ASH Annual Meeting and Exposition highlight the emerging role CAR T-cell therapies have in treating certain types of aggressive, refractory blood cancers.

Research in Review

Researchers report significantly improved response rates in patients with CLL treated with concurrent targeted therapy and CAR-T therapy.
Pembrolizumab improves response to chimeric antigen receptor T-cell treatments in pediatric patients with B-cell relapsed acute lymphoblastic leukemia.
Patients with relapsed or refractory lymphoma who achieve durable remission after low-dose conditioning chemotherapy and CAR T-cell therapy tend to have high serum levels of a particular protein.
The authors review the foundational research in CAR-T therapy.
Subscribe to CAR-T Therapies